Home › Funds › Kennondale Capital Management LLC › IKT
Kennondale Capital Management LLC position in IKT
INHIBIKASE THERAPEUTICS INC COM NEW · Health Care
Kennondale Capital Management LLC reported holding 721,961 shares of IKT (INHIBIKASE THERAPEUTICS INC COM NEW) in its Q3 2026 13F filing — a position valued at US$1.5M, representing 0.96% of its reported portfolio and ranking #44 among its reported holdings. Kennondale Capital Management LLC has disclosed IKT holdings in 2 of the last 2 reported quarters, going back to Q2 2026.
Last updated: 2026-11-10 · Source: SEC EDGAR Form 13F-HR
How Kennondale Capital Management LLC's IKT position evolved
Kennondale Capital Management LLC first disclosed a stake in IKT in Q2 2026 at 565,983 shares (US$1.1M). The position peaked in Q3 2026 at 721,961 shares, worth US$1.5M. Across 2 filings, Kennondale Capital Management LLC increased the stake 1 time(s), trimmed it 0 time(s) and left it unchanged 0 time(s). The most recent filing (Q3 2026) shows 721,961 shares valued at US$1.5M — an increase of 155,978 shares quarter over quarter.. Notable position changes include a 28% increase in Q3 2026 (shares fell 18% over the following quarter).
Quarter by quarter
| Quarter | Shares | Value | Change |
|---|---|---|---|
| Q2 2026 | 565.98K | $1.15M | New |
| Q3 2026 | 721.96K | $1.48M | Add |
Dots on the line are colored by change type; missing quarters mean no position was reported.
About IKT and 13F data
IKT (INHIBIKASE THERAPEUTICS INC COM NEW) is a Health Care company. 69 other funds we track also report a position in IKT — the largest reported positions include Sands Capital Alternatives, LLC (US$26.4M), Soleus Capital Management, L.P. (US$22.1M), Trails Edge Capital Partners, LP (US$18.4M). Under SEC rules, institutional investment managers with over $100M in assets must file Form 13F within 45 days of each quarter-end, disclosing long positions in US-listed equities. The data excludes short positions, most options and foreign holdings, so treat it as a quarterly snapshot rather than a live position.
Other funds holding IKT
- Sands Capital Alternatives, LLC 13.02M sh · $26.43M · Q2 2026
- Soleus Capital Management, L.P. 10.88M sh · $22.08M · Q2 2026
- Trails Edge Capital Partners, LP 9.05M sh · $18.37M · Q2 2026
- Fairmount Funds Management LLC 8.62M sh · $17.51M · Q2 2026
- ADAR1 Capital Management, LLC 7.39M sh · $15.00M · Q2 2026
- Commodore Capital LP 5.40M sh · $10.96M · Q2 2026
- Saturn V Capital Management LP 3.87M sh · $7.85M · Q2 2026
- Kalehua Capital Management LLC 3.82M sh · $7.76M · Q2 2026
- Spruce Street Capital LP 3.58M sh · $7.27M · Q2 2026
- Squadron Capital Management LLC 3.00M sh · $6.09M · Q2 2026
- Stonepine Capital Management, LLC 396.18K sh · $804.24K · Q2 2026
More on Kennondale Capital Management LLC
FAQ
How long has Kennondale Capital Management LLC held IKT?
Kennondale Capital Management LLC has disclosed IKT holdings in 2 of the last 2 reported quarters, going back to Q2 2026.
What is Kennondale Capital Management LLC's current position in IKT?
As of Q3 2026, Kennondale Capital Management LLC holds 721.96K shares of IKT (INHIBIKASE THERAPEUTICS INC COM NEW), valued at $1.48M, representing 0.96% of its reported portfolio and ranking #44.
Has Kennondale Capital Management LLC been buying or selling IKT?
In the latest 13F filing (Q3 2026), Kennondale Capital Management LLC increased its position in IKT. The position peaked in Q3 2026 at 721.96K shares.
Which other funds hold IKT?
Other major institutional holders of IKT include Sands Capital Alternatives, LLC, Soleus Capital Management, L.P., Trails Edge Capital Partners, LP, among 69 funds with disclosed positions.
Where does this data come from?
All figures are computed from SEC Form 13F quarterly filings, which institutional investment managers must file within 45 days of quarter end for long positions of $100,000 or more.